Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEC2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $62,908
Award facts
- Contract value 100% obligated
- $62,907.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $62,907.84 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. The delivery order, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. This award is issued under the company's single-award Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.9 billion ceiling and extends through December 31, 2036.
DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier within the DLA's broader $30.3 billion PPV-G GEN V acquisition strategy, which supports recurring medical supply needs across Department of Defense healthcare facilities worldwide. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, with Xolair—an immunosuppressant biologic agent—representing one of many specialized therapeutic products delivered under the indefinite delivery contract framework. No subcontractors are identified in this award documentation, with DMS Pharmaceutical Group operating as the sole performer for this delivery order.
Quick answers
Who was awarded contract SPE2DR26FMEC2?
SPE2DR26FMEC2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FMEC2 worth?
The government has obligated $62,908 on SPE2DR26FMEC2.
Is contract SPE2DR26FMEC2 an order under another contract?
Yes. SPE2DR26FMEC2 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEC2 competed?
The extent of competition for SPE2DR26FMEC2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award